1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Demographic and clinical characteristics of the study groupsa
MS (n = 30)dNPSLE (n = 23)HC (n = 43)P Valueb
Female sex (No.) (%)23 (76.5%)22 (95.7)37 (86.0).150
Age (yr) (mean) (SD)43.8 (8.6)48.9 (12.5)44.7 (9.8).170
Disease duration (yr) (mean) (SD)11.7 (8)15 (9.6)NA.237
SLAM checklist (mean) (SD)NA9.9 (4.9)NANA
EDSS (median) (IQR)3.3 (2.1–6.0)NANANA
  • Note:—NA indicates not applicable; dNPSLE, neuropsychiatric systemic lupus erythematosus with diffuse syndromes; SLAM, systemic lupus activity measure; EDSS, Expanded Disability Status Scale; IQR, interquartile range.
  • ↵a Disease-modifying medications for treatment of MS included interferon β (n = 18). natalizumab (n = 8), and glatiramer acetate (n = 4). Other treatment included antianxiety (dNPSLE, n = 2; MS, n = 0), antiepileptic (dNPSLE, n = 0; MS, n = 5), antidepressants (dNPSLE, n = 10: MS, n = 11), antifatigue (dNPSLE, n = 0; MS, n = 4), antispastic (dNPSLE, n = 0; MS, n = 8), antiparesthesia (dNPSLE, n = 0; MS, n = 8), hydroxychloroquine (Plaquenil) (dNPSLE, n = 21), imuran (dNPSLE, n = 4), immunosuppressive (dNPSLE, n = 21; MS, n = 5), steroids or nonsteroidal antiinflammatory drugs (dNPSLE, n = 17; MS n = 1).
  • ↵b The χ2 test was used to evaluate significant differences in sex distribution among the groups, and analysis of variance was used to evaluate significant differences in age and disease duration.